These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence?
    Author: Dixon JM.
    Journal: Breast; 2008 Aug; 17(4):353-60. PubMed ID: 18490163.
    Abstract:
    In early breast cancer, excision of the primary tumor, with or without radiotherapy and adjuvant chemotherapy or tamoxifen, is highly effective and yields long-term disease control for many patients. Some patients relapse early (within 2 years of surgery); such relapses are predominantly distant metastases and are associated with an increased risk for breast cancer-related mortality. The aromatase inhibitors (anastrozole, letrozole, and exemestane) have been shown to be superior to tamoxifen in improving disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Anastrozole and letrozole are approved in the initial adjuvant setting, and their use appears to be a better option than initial tamoxifen for preventing disease recurrence in the first 2 years of therapy, the peak time for recurrence and metastases. This review compares the ability of aromatase to prevent early recurrences, particularly distant metastases.
    [Abstract] [Full Text] [Related] [New Search]